Pharmaceutical Compositions Comprising Ribose and Amino Acids

A ribose and amino acid composition enhances antibiotic susceptibility and efficacy against multiply resistant bacteria, addressing the challenge of antimicrobial resistance in urinary tract infections.

JP2024545819AActive Publication Date: 2024-12-12メー-フ ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024538070
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-20
Filing Date
2022-11-02
Publication Date
2024-12-12
Estimated Expiration
2042-11-02

AI Technical Summary

Technical Problem

The increasing prevalence and antimicrobial resistance of bacterial infections, particularly urinary tract, respiratory, soft tissue, and bone infections caused by bacteria such as E. coli and Klebsiella pneumoniae, pose a significant challenge due to high recurrence rates and limited effectiveness of existing treatments.

Method used

A composition comprising ribose and specific amino acids (glycine, alanine, and glutamine) in an aqueous solution, administered concurrently with antibiotics, enhances bacterial susceptibility to antibiotic treatment, particularly for multiply resistant strains.

Benefits of technology

The composition significantly reduces bacterial growth and improves survival rates in animal models and demonstrates potential clinical efficacy in treating recurrent urinary tract infections by enhancing antibiotic effectiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545819000006
    Figure 2024545819000006
  • Figure 2024545819000007
    Figure 2024545819000007
  • Figure 2024545819000008
    Figure 2024545819000008
Patent Text Reader

Abstract

The present invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient, the composition comprising ribose and the amino acids glycine, alanine, and glutamine in an aqueous solution, the method comprising orally administering the composition to a patient who is further being treated with an antibiotic.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient. [Background technology]

[0002] Urinary tract infections are the most common bacterial disease worldwide. The community-acquired prevalence is 0.7%. The frequency of healthcare-associated UTIs in healthcare-associated infections is 12.9% in the United States, 19.6% in Western Europe, and 24% in developing countries. In urology, the prevalence is 5.1%. Urinary tract infections are frequently caused by both gram-negative and gram-positive bacteria, frequently Escherichia Coli and Klebsiella pneumoniae. With high recurrence rates and increasing antibiotic resistance of uropathogens, the burden of these infections is likely to increase significantly. Summary of the Invention

[0003] The present invention proposes a new treatment for bacterial infections selected from bacterial urinary tract infections, bacterial respiratory infections, bacterial soft tissue infections, and bacterial bone infections. In particular, the present invention proposes a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient, the composition comprising ribose and the amino acids glycine, alanine, and glutamine in an aqueous solution, the method comprising orally administering the composition to a patient who is being co-treated with an antibiotic. Preferably, the infection being treated is a bacterial urinary tract infection. Ribose is preferably D-ribose. Alanine is preferably racemic (D / L)-alanine. Glutamine is preferably L-glutamine. The concentration of ribose in the aqueous solution of the composition is preferably between 30 and 40 g / l. The concentration of glycine in the aqueous solution of the composition is preferably between 1.5 and 2.5 g / l. The concentration of alanine in the aqueous solution of the composition is preferably between 15 and 25 g / l. The concentration of glutamine in the aqueous solution of the composition is preferably between 20 and 30 g / l. The relative concentrations of amino acids in the aqueous solution of the composition are preferably 1:8 to 12:10 to 15 (glycine:alanine:glutamine). The relative concentrations of ribose and the amino acids glycine, alanine, and glutamine in the aqueous solution of the composition are preferably 1:0.8 to 2.0 (ribose:amino acids). The volume of the aqueous solution of the composition is preferably 5 to 50 ml, preferably 10 to 30 ml.

[0004] In a preferred embodiment, the composition is administered to the patient two or three times daily. Twice daily administration is most preferred. In an embodiment, the composition may be administered to the patient daily for 1-3 weeks, preferably 1-2 weeks. The amount of ribose administered to a patient per day is preferably between 1200 and 2400 mg. The amount of glycine administered to a patient per day is preferably between 60 and 150 mg. The amount of alanine administered to a patient per day is preferably between 600 and 1500 mg. The amount of glutamine administered to a patient per day is preferably between 800 and 1800 mg. The relative amounts of amino acids administered to a patient are preferably 1:8 to 12:10 to 15 (glycine:alanine:glutamine). The relative amounts of ribose and the amino acids glycine, alanine, and glutamine administered to a patient are preferably 1:0.8 to 2.0 (ribose:amino acids). The patient is preferably a human patient. In particular, the human patient may be an adult over the age of 18.

[0005] In one embodiment, the composition may be used in the treatment of infections caused by bacterial strains with multiple antibiotic resistance, in particular E. coli or Klebsiella pneumoniae bacterial strains with multiple antibiotic resistance. It has previously been proposed in DE 10 2011105594 that compositions containing ribose, glycine, alanine and glutamine may have beneficial effects in the treatment of infections caused by bacteria resistant to multiple antibiotics. The method generally includes treating the patient with an antibiotic in addition to simultaneously treating the patient with the composition of the present invention. The composition of the present invention is intended to enhance the effect of the antibiotic. In one embodiment, the composition of the present invention is administered simultaneously with every or every other dose of the antibiotic. In another embodiment, the composition of the present invention is administered at least 30 minutes and at most 5 hours before every or every other dose of the antibiotic. This is because the composition may increase the susceptibility of bacteria to antibiotic treatment, and the composition should be allowed to act on the bacteria before the antibiotic is administered.

[0006] The antibiotics administered to the patient may be penicillins, especially ampicillin, cephalosporin antibiotics such as cefazolin, fluoroquinolone antibiotics such as ciprofloxacin, and sulfonamides such as sulfamethoxazole, optionally in combination with trimethoprim. The aqueous solution forming the composition can be obtained by dissolving a mixed lyophilisate of amino acids in an aqueous solution of ribose. The mixed lyophilisate can be obtained by lyophilising a solution containing the amino acids glycine, alanine and glutamine in the appropriate ratio. Further details and advantages of the invention are described with reference to the following examples and drawings. [Brief description of the drawings]

[0007] [Figure 1a] FIG. 1 shows plots of results for Strain No. 1 and Antibiotic No. 1 from the in vitro studies described below. [Figure 1b]FIG. 1 shows plots of results for Strain #1 and Antibiotic #2 from the in vitro studies described below. [Figure 1c] FIG. 1 shows plots of results for Strain #1 and Antibiotic #3 from the in vitro studies described below. [Figure 1d] FIG. 1 shows plots of results for Strain #1 and Antibiotic #4 from the in vitro studies described below. [Figure 2a] FIG. 1 shows result plots for Strain No. 2 and Antibiotic No. 1 from the in vitro study described below. [Figure 2b] FIG. 1 shows plots of results for Strain No. 2 and Antibiotic No. 2 from the in vitro study described below. [Figure 2c] FIG. 1 shows plots of results for strain no. 2 and antibiotic no. 3 from the in vitro study described below. [Figure 2d] FIG. 1 shows plots of results for strain no. 2 and antibiotic no. 4 from the in vitro studies described below. [Figure 3a] FIG. 1 shows result plots for Strain No. 3 and Antibiotic No. 1 from the in vitro studies described below. [Figure 3b] FIG. 1 shows plots of results for Strain No. 3 and Antibiotic No. 2 from the in vitro studies described below. [Figure 3c] FIG. 1 shows plots of results for Strain No. 3 and Antibiotic No. 3 from the in vitro studies described below. [Figure 3d] FIG. 1 shows plots of results for strain no. 3 and antibiotic no. 4 from the in vitro studies described below. [Figure 4a] FIG. 1 shows result plots for Strain No. 4 and Antibiotic No. 1 from the in vitro study described below. [Figure 4b] FIG. 1 shows result plots for Strain No. 4 and Antibiotic No. 2 from the in vitro study described below. [Figure 4c] FIG. 1 shows plots of results for Strain No. 4 and Antibiotic No. 3 from the in vitro studies described below. [Figure 4d]FIG. 1 shows plots of results for Strain No. 4 and Antibiotic No. 4 from the in vitro studies described below. [Diagram 5] FIG. 13 shows result plots for in vivo study no. 2. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] composition An aqueous composition was obtained by mixing one vial of the lyophilisate as described in Table 1 below together with two ampoules of a 3.5% solution of D-ribose as described in Table 2 below. [Table 1]

[0009] [Table 2]

[0010] After mixing one lyophilisate vial and two ribose solution vials together, a liquid composition according to the description in Table 3 was obtained. [Table 3] The resulting composition was subjected to several in vitro and in vivo mouse model studies.

[0011] In vitro studies The effect of the composition on antibiotic susceptibility was tested in vitro on four resistant bacterial strains. This study was performed as described in Ostrosky EA, Mizumoto MK, Lima MEL, Kaneko TM, Nishikawa SO, Freitas BR Rev Bras Farmacogn (2008) 18:301-307. Each purified bacterial strain was inoculated into a nutrient broth medium and incubated overnight (18-20 hours), then bacterial suspensions were prepared and the turbidity was adjusted to 0.2-0.25 at 360 nm. The concentrations of antibiotics used along with the bacterial strains during the 8-day treatment are shown in Table 1. Details of the panel of different treatments in the presence of different antibiotics and compositions of the present invention against resistant strains are shown in Table 2.

[0012] [Table 4]

[0013] [Table 5]

[0014] All vials were incubated at 37° C. After the initial 24 hours, the total number of bacteria in each vial was monitored daily using a spectrophotometer at 630 nm. The results are shown in Figures 1a to 4d. In detail, Figure 1a shows the results for strain number 1 and antibiotic number 1. Figure 1b shows the results for strain number 1 and antibiotic number 2. Figure 1c shows the results for strain number 1 and antibiotic number 3. Figure 1d shows the results for strain number 1 and antibiotic number 4. Figure 2a shows the results for strain number 2 and antibiotic number 1. Figure 2b shows the results for strain number 2 and antibiotic number 2. Figure 2c shows the results for strain number 2 and antibiotic number 3. Figure 2d shows the results for strain number 2 and antibiotic number 4. Figure 3a shows the results for strain number 3 and antibiotic number 1. Figure 3b shows the results for strain number 3 and antibiotic number 2. Figure 3c shows the results for strain number 3 and antibiotic number 3. Figure 3d shows the results for strain number 3 and antibiotic number 4. Figure 4a shows the results for strain number 4 and antibiotic number 1. Figure 4b shows the results for strain number 4 and antibiotic number 2. Figure 4c shows the results for strain number 4 and antibiotic number 3. Figure 4d shows the results for strain number 4 and antibiotic number 4. As can be seen from the figure, the co-treatment group shows a significant reduction in bacterial growth within 2-3 days of treatment, while antibiotic treatment alone does not show a significant effect compared to the control.Treatment with the composition of the present invention alone also does not show a significant effect compared to the control.This suggests that the composition of the present invention helps resistant bacteria become more susceptible to antibiotic attack.

[0015] In vivo Animal Study No. 1 A group of Sprague-Dawley rats was infected with an antibiotic-resistant Staphylococcus aureus (MRSA L2-15 ST 13DSMZ46320) strain (i.p., 1 × 10 6 CFU / rats augmented with 6% porcine mucin type III), subgroups of 10 rats (5 males and 5 females) were either untreated, treated with 10 mg / kg / day (orally) of the antibiotic rifampicin for 10 consecutive days, co-treated with 10 mg / kg / day (orally) of the antibiotic rifampicin and 250 mg / kg / day (orally) of the composition of the invention for 10 consecutive days (250 mg means the mass of the lyophilisate in Table 1 contained in the amount of mixed solution administered), or co-treated with 10 mg / kg / day (orally) of the antibiotic rifampicin and 500 mg / kg / day (orally) of the composition of the invention for 10 consecutive days. Survival after 10 days was recorded. In the untreated group, no animals survived after 10 days. In the group treated with antibiotics only, 2 out of 10 animals survived. In the concurrent treatment with 250 mg / kg / day of the composition of the present invention, 7 out of 10 animals survived. In the concurrent treatment with 500 mg / kg / day of the composition of the present invention, all animals survived.

[0016] In vivo Animal Study No. 2 Male Wistar rats weighing 200-250 g were infected with a resistant strain of E. coli (O157.H7) using the granulation pouch model. In detail, pouches were generated by injecting 30 ml of sterile filtered air, followed by a deep injection of 0.5 ml of 0.5% croton oil in sesame oil into the dorsal loose connective tissue. After 2 days, approximately 10 ml of air was aspirated, and after a further 2 days, the pouch was injected with 2 ml of a saline solution of 1% peptone and 0.35% agar. On day 10, the rats were inoculated with 10 ml of E. coli suspended in 1.5 ml of THB containing 2.5% gastric mucin and 0.35% agar. 6 CFU were infected. The rats were divided into groups of 5 and administered the following drugs either alone or together, starting 24 hours after infection, every 12 hours for 3 consecutive days, for a total of 6 doses: Co-trimoxazole (Septrin, GlaxoSmithKline) 30 mg / kg (intraperitoneally) and the composition of the invention 500 mg / kg (orally) (500 mg means the mass of the lyophilisate in Table 1 contained in the amount of mixed solution administered). A control group of 5 untreated control animals received 6 oral doses of placebo and intraperitoneal injections of saline at the same intervals.

[0017] Bursal fluid samples (0.5 mL) were aspirated from each animal immediately before treatment (0 h), 3 h after the first dose, immediately before the last dose, and 3 and 24 h after the last dose. Bursal fluid was diluted 6 times 10-fold with 1% peptone in saline solution, and 10 μl of each diluted and undiluted bursal fluid was spread in duplicate on the surface of blood agar plates and incubated at 37°C for 24 h. Results represent the mean values ​​obtained from all animals in the same group at the same intervals and expressed as log10 CFU / ml. Following standard analysis of variance, one-way analysis of variance and Bonferroni multiple comparison test were used to identify significant differences at the 0.05 level. The efficacy of treatment according to bacterial counts is shown in the figures. There was no significant difference between the control group and the groups treated with the composition of the invention alone and with cotrimoxazole alone at all time intervals. A 0.93 Log reduction (p≦0.01) in bacterial counts in the groups tested with the composition of the invention and cotrimoxazole was observed as early as 3 hours after the first dose. This reduction effect increased with successive doses, reaching a 3.6 Log reduction (p≦0.01) before the last dose (6th dose) and persisting at a 4.3 Log reduction (p≦0.01) compared to the control group 24 hours after the last dose. Even when the difference from the initial count was used as the response measurement, the groups treated with cotrimoxazole and the composition of the invention were significantly lower than the control group at all time points.

[0018] Clinical Trials The proposed Phase II clinical trial design will include several patients with bacterial urinary tract infections. Patients will be treated with a combination of the composition of the present invention (20 ml of combined solution administered twice daily according to Table 3 above) and appropriate antibiotics for 10 days. Results will be evaluated and benchmarked against antibiotic treatment alone. In detail, the study design is as follows. Phase II Indications: Recurrent urinary tract infections the purpose: Primary Objective: To evaluate the safety of the compositions of the present invention and to evaluate the effect of the compositions of the present invention in combination with antimicrobial treatment on urine cultures (microbiological cure, no microbial growth in 24-48 hour cultures). Secondary objective: To evaluate the effect of the compositions of the present invention in combination with antibacterial treatment on disease-related symptoms (clinical cure, disappearance of symptoms and signs).

[0019] Design: Randomized, double-blind, placebo-controlled, multicenter study. Patients with recurrent urinary tract infections will receive a blinded oral dose of the composition of the invention or a matching placebo twice daily for 10 days in addition to empirical antibiotics. Population: Male and female patients diagnosed with recurrent urinary tract infections over the age of 18. Sample size: 100 patients from each center. Dosage regimen: All patients will receive the following: 1. Trimethoprim-sulfamethoxazole 160 / 800 mg orally twice daily every 12 hours for 10 days. 2. A composition of the invention or placebo (according to randomization), twice daily, every 12 hours, orally, for 10 days.

[0020] Efficacy Data: - Complete response is defined as clinical cure (disappearance of symptoms and signs) and microbiological cure (negative urine culture) 5-7 days after the end of treatment. - Incomplete response is defined as clinical recovery (disappearance of symptoms and signs) accompanied by a positive bacterial culture 5 to 7 days after the end of treatment. - Failure is defined as the absence of clinical response within 5 days after initiation of treatment. - Relapse is the appearance of a new symptom of urinary tract infection 60 ± 10 days after the first day of study drug administration in a patient who was previously clinically and microbiologically cured with a positive urine culture. Safety data: Adverse events reported by the subject or observed by the observer.

[0021] statistics: The primary validity analysis will use reliability procedures. Two-sided confidence intervals will be calculated for response frequencies (e.g. Clopper-Pearson method). Paired t-tests will be applied as secondary efficacy analysis. Adverse events will be summarized in frequency tables and classified by body system. Frequency tables by treatment group will show all treatment-emergent adverse events (TEAEs), all possible related TEAEs, and all adverse events during treatment. These will be analyzed by the intensity of the adverse event, with pre- and post-treatment adverse events presented in the subject list. P-values ​​will be used to identify possible significant adverse events. Treatment group comparisons of adverse event frequencies were examined with Fisher's exact test. Test period: The study is expected to last 18 months. The treatment period will be 10 days, after which each patient will be followed for 8 weeks.

Claims

1. 1. A composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory infection, a bacterial soft tissue infection, and a bacterial bone infection in a patient, the composition comprising ribose and the amino acids glycine, alanine, and glutamine in an aqueous solution, the method comprising orally administering the composition to the patient who is being co-treated with an antibiotic.

2. The composition for use according to claim 1, wherein the ribose is D-ribose and / or the alanine is racemic (D / L)-alanine and / or the glutamine is L-glutamine.

3. the concentration of ribose in the aqueous solution of the composition is between 30 and 40 g / l, and / or the concentration of glycine in the aqueous solution of the composition is between 1.5 and 2.5 g / l; and / or the concentration of alanine in the aqueous solution of the composition is between 15 and 25 g / l, and / or The composition for use according to claim 1 or 2, wherein the concentration of glutamine in the aqueous solution of said composition is between 20 and 30 g / l.

4. The composition for use according to any one of claims 1 to 3, wherein the relative concentrations of the amino acids in the aqueous solution of the composition are 1:8-12:10-15 (glycine:alanine:glutamine).

5. 5. The composition for use according to any one of claims 1 to 4, wherein the relative concentrations of the ribose and the amino acids glycine, alanine and glutamine in an aqueous solution of the composition is 1:0.8-2.0 (ribose:amino acids).

6. The composition for use according to any one of claims 1 to 5, wherein the volume of the aqueous solution of the composition is between 10 and 30 ml.

7. The composition for use according to any one of claims 1 to 6, which is administered to the patient two or three times a day and / or administered to the patient daily for 1 to 3 weeks.

8. the amount of ribose administered to the patient per day is between 1200 and 2400 mg; or the amount of glycine administered to said patient per day is between 60 and 150 mg; or the amount of alanine administered to said patient per day is between 600 and 1500 mg; or The composition for use according to any one of claims 1 to 7, wherein the amount of glutamine administered to the patient per day is between 800 and 1800 mg.

9. 9. A composition for use according to any one of claims 1 to 8, wherein the relative amounts of the amino acids administered to the patient are 1:8-12:10-15 (glycine:alanine:glutamine).

10. 10. The composition for use according to any one of claims 1 to 9, wherein the relative amounts of the ribose and the amino acids glycine, alanine and glutamine administered to the patient is 1:0.8-2.0 (ribose:amino acids).

11. 11. The composition for use according to any one of claims 1 to 10, wherein the antibiotics co-administered to the patient may be penicillins, particularly ampicillin, cephalosporin antibiotics such as cefazolin, fluoroquinolone antibiotics such as ciprofloxacin, and sulfonamides such as sulfamethoxazole, optionally in combination with trimethoprim.

12. The composition for use according to any one of claims 1 to 11, wherein the infection is a urinary tract infection.

13. 13. The composition for use according to any one of claims 1 to 12, wherein the infection is caused by a bacterial strain with multiple resistance to antibiotics, in particular Escherichia Coli or Klebsiella Pneumoniae with multiple resistance to antibiotics.

14. A composition for use according to any one of claims 1 to 13, co-administered with every or every other dose of an antibiotic.

15. The composition for use according to any one of claims 1 to 13, which is administered at least 30 minutes and at most 5 hours before each or every other dose of antibiotic.

Citation Information

Patent Citations

  • Mixture of substances comprising ribose and amino acids for treating sepsis, coagulopathies, bone healing disorders and / or bone bleeding

    EP2826483A2

  • Mixture and infusion or drink solution

    US20120329734A1